SGLT2 inhibitors linked to lower risk of kidney stones in patients with type 2 diabetes


Rates of kidney stones are increasing globally, especially in the United States. A study led by the Mass General Brigham investigators found an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of kidney stones. The data from three nationwide databases of patients with type 2 diabetes showed that those taking SGLT2 inhibitors had a 30% lower risk of developing kidney stones than those taking other classes of diabetes medications. These findings could help guide clinical decision-making for patients with diabetes at risk of developing kidney stones. The study was published in JAMA Internal Medicine.

Source link

error: Content is protected !!